“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of
Producing high quality affordable
and accessible biologics
Mumbai, July 02, 2015: Pharma Major Lupin Limited today announced the acquisition of 100% equity stake in
ZAO “Biocom” in Russia subject to certain closing conditions. The acquisition marks Lupin’s foray into the
Russian pharmaceutical market which recorded RUB 765 billion in sales, placing it as one of the Top 10
pharmaceutical markets in the world in 2014 (IMS Health). For over a decade, Russian pharmaceutical market
recorded double digit growth and expected to continue with this trend, projecting Russia to be one of the Top 8
pharmaceutical markets in the world by 2018 (IMS Health).
Established in 1991, Biocom is a fast growing generic pharmaceutical company with a major focus on therapies
such as cardiovascular, central nervous system and antimicrobials for systemic use and also does contract
manufacturing and secondary packaging. The Company recorded sales of RUB 861.2 million in financial year
2014 and has 118 employees. Biocom operates a modern European GMP compliant plant and was also one of
the first Russian pharmaceutical manufacturing companies to receive an approved manufacturer status from the
World Health Organization (WHO) in 2013.
Commenting on the acquisition, Ms. Vinita Gupta, Chief Executive Officer of Lupin Limited said, “We are excited
about our entry into the Russian market through Biocom. Russia is an attractive market and this acquisition will
also enable our expansion into neighboring markets as well as other Eastern European markets in the future.”
Dr. Maurice Chagnaud, President‐Europe and Head of Inhalation Strategy, commented, “Biocom is a fast
growing pharmaceutical player and has recorded very positive results over the past five years. The acquisition
also provides us with a strong platform to grow into the Russian market and has a lot of synergy with Lupin’s
global research, technology, manufacturing and commercial expertise not to mention our global high quality
product pipeline, all of which we shall leverage to grow Biocom into a market leader in the years to come.”
Mr. Aleksandr Sergeyev, Biocom’s executive officer, commented, “I am delighted with Biocom’s association with
Lupin. Having found, built and developed Biocom together with Mr. Igor Rudinskiy for so long, I firmly believe
that the future and growth of Biocom would be best handled by the management and technology expertise that
Lupin brings to table. I wish Biocom and Lupin the very best in their future endeavors.”
About Lupin Limited
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of
branded and generic formulations as well as biotechnology products and APIs globally. The Company is a
significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space
and holds global leadership positions in the Anti-TB and Cephalosporin segment.
Lupin is the 5th largest and fastest growing top 5 generics player in the US (5.3% market share by prescriptions,
IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The Company is also amongst the top
10 generic pharmaceutical players in Japan and South Africa (IMS).
For the financial year ended March 2015, Lupin's Consolidated turnover and Profit after Tax were Rs. 125,997 million (USD 2.06 billion) and Rs. 24,032 million (USD 393 million) respectively. Please visit http://www.lupin.com for more information.
CIN: L24100MH1983PLC029442 Registered Office: 159, C.S.T. Road, Kalina, Santacruz (East), Mumbai - 400 098.
You could also follow us on Twitter – www.twitter.com/lupinlimited
For more information, please contact –
Head – Corporate Communications
Ph: +91-98 20 338 555
Head – M & A and Investor Relations
Ph: +91 98 20 023 511
Safe Harbor Statement